ArtVentive received its CE European Union approval for its ArtVentive EOS™ Plug in 2013, and FDA clearance in 2014, paving the way for the global expansion of the marketing and sales of the ArtVentive EOS™ Plug. ArtVentive is committed to capitalizing on the significant opportunities within the global health care industry.
Clinical data of embolization cases are reported in multiple published articles and presented at leading international medical conferences (see: http://s316804825.onlinehome.us/products/publications/), highlighting the unique feature of the EOS™ Plug: immediate occlusion.
Safe, effective and precise placement in the vessel, provides immediate and permanent occlusion, without distal migration and with the opportunity to shorten procedure time, to reduce the number of devices used while reducing radiation exposure and the use of contrast agent (see: http://s316804825.onlinehome.us/products/testimonials/).
To date the EOS™ Plug is sold to hospitals in the US via a direct sales team, and in most European countries, Israel, Australia, and New Zealand via our international distributing partners.
Currently we are preparing to enter the market in Latin America, while there are serious inquiries in regions with potential growth: Korea, Japan, Vietnam, China, India, and Singapore.
For more information regarding investor relations, please contact Mr. Leon Rudakov, PhD, President and CTO, via email: info@artventivemedical.com
or fax: +1-650-240-1706.
